Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma, a biotechnology company that develops treatments for neurological disorders, cancer, autoimmune and infectious diseases, has completed manufacturing the first batch of its prescription pain reliever, Nyloxin Rx, and has released it for initial marketing-related distribution within the US.
Subscribe to our email newsletter
Nutra Pharma said that Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.
The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating angina pectoris, angina faucium, back pain, headaches, joint pain, migraines, neck pain, neuralgia, ovarian pain, and painful periods and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “As we move forward with the launch of Nyloxin Rx, we continue to seek partnerships with established U.S. and international distributors to assist us with ongoing marketing to physician offices, hospitals and medical clinics.”